CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape
A roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.
EP: 1.The Evolving Landscape of Newly Diagnosed Multiple Myeloma
EP: 2.Highlights from ASH 2023 in Transplant-Eligible NDMM
EP: 3.Advances in the Treatment of High-Risk MM
EP: 4.Role of Transplant and MRD in Newly Diagnosed MM
EP: 5.The Evolving Treatment Paradigm for Transplant Ineligible MM
EP: 6.Treatment of Multiple Myeloma at Early Relapse
EP: 7.Potential Role for CAR T-Cell Therapy in MM at Early Relapse
EP: 8.Updates on BCMA-Targeting Bispecifics in MM
EP: 9.Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma
EP: 10.Step-Up Dosing Practices for Bispecifics in Multiple Myeloma
EP: 11.Adverse Effects Related to Bispecifics in Multiple Myeloma
EP: 12.GPRC5D-Targeting Bispecifics in Multiple Myeloma
EP: 13.CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape
EP: 14.Treatment Considerations and Sequencing in Multiple Myeloma
This is a video synopsis/summary of a Peer Exchange featuring Krina K. Patel, MD, MSc; Amrita Krishnan, MD; Caitlin Costello, MD; Saad Z. Usmani, MD, MBA, FACP; and Rafat Abonour, MD.
The discussion focuses on newer data with B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy in later lines of therapy for relapsed/refractory multiple myeloma, demonstrating median progression-free survival over 2 years, which is unprecedented in this setting. Combinations of CAR T-cell therapy with other novel agents like bispecific antibodies are planned to further improve the depth and durability of response.
However, higher-grade cytokine release syndrome and neurotoxicity remains an issue with CAR T-cell therapy vs bispecific antibodies. Careful patient selection and disease debulking prior to cell infusion is important to mitigate toxicity. Additional therapy soon after CAR T-cell therapy may improve sustained responses, but optimal bridging therapy and sequencing requires further study given concerns over T-cell exhaustion or exacerbating cytopenias.
Video synopsis is AI-generated and reviewed by OncLive® editorial staff.
